| Dr Mary Elizabeth Gerard, MD | |
|
333 N 18th Ave Ste B4, Pocatello, ID 83201 | |
| (208) 232-2233 | |
| (208) 232-2299 |
| Full Name | Dr Mary Elizabeth Gerard |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 33 Years |
| Location | 333 N 18th Ave Ste B4, Pocatello, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578667739 | NPI | - | NPPES |
| 002119100 | Medicaid | ID | |
| 70599 | Other | ID | BLUE CROSS |
| 000010008867 | Other | ID | BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | M7059 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bingham Memorial Hospital | Blackfoot, ID | Hospital |
| Portneuf Medical Center | Pocatello, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bmh Inc | 8426149758 | 124 |
| Pocatello Health Services Llc | 6608927637 | 136 |
News Archive
Vitro Diagnostics, Inc., dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world.
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.
Higher doses of second-generation antipsychotics and more severe negative symptoms are associated with lower levels of oxytocin in cerebrospinal fluid among patients with schizophrenia, researchers report.
BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.
The Canadian Red Cross is reminding all individuals and families about the importance of emergency preparedness, after a tornado touched down in the City of Vaughan last night.
› Verified 6 days ago
| Entity Name | Bmh Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255539193 PECOS PAC ID: 8426149758 Enrollment ID: O20071018000897 |
News Archive
Vitro Diagnostics, Inc., dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world.
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.
Higher doses of second-generation antipsychotics and more severe negative symptoms are associated with lower levels of oxytocin in cerebrospinal fluid among patients with schizophrenia, researchers report.
BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.
The Canadian Red Cross is reminding all individuals and families about the importance of emergency preparedness, after a tornado touched down in the City of Vaughan last night.
› Verified 6 days ago
| Entity Name | Pocatello Health Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689802852 PECOS PAC ID: 6608927637 Enrollment ID: O20090701000646 |
News Archive
Vitro Diagnostics, Inc., dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world.
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.
Higher doses of second-generation antipsychotics and more severe negative symptoms are associated with lower levels of oxytocin in cerebrospinal fluid among patients with schizophrenia, researchers report.
BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.
The Canadian Red Cross is reminding all individuals and families about the importance of emergency preparedness, after a tornado touched down in the City of Vaughan last night.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mary Elizabeth Gerard, MD 333 N 18th Ave, Ste B4, Pocatello, ID 83201 Ph: (208) 232-2233 | Dr Mary Elizabeth Gerard, MD 333 N 18th Ave Ste B4, Pocatello, ID 83201 Ph: (208) 232-2233 |
News Archive
Vitro Diagnostics, Inc., dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world.
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.
Higher doses of second-generation antipsychotics and more severe negative symptoms are associated with lower levels of oxytocin in cerebrospinal fluid among patients with schizophrenia, researchers report.
BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.
The Canadian Red Cross is reminding all individuals and families about the importance of emergency preparedness, after a tornado touched down in the City of Vaughan last night.
› Verified 6 days ago
Christian F. Schmutz, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1350 Baldy Ave Ste A, Pocatello, ID 83201 Phone: 208-346-7500 Fax: 208-346-7501 | |
Dr. Robert Michael Kennedy, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 777 Hospital Way, G15, Pocatello, ID 83201 Phone: 208-239-2722 Fax: 208-239-3759 | |
Dr. Kathleen Anne Erwin, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 777 Hospital Way, Pocatello, ID 83201 Phone: 208-239-2571 Fax: 208-239-3665 | |
Dr. William Hazle, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 500 S 11th Ave, Pocatello, ID 83201 Phone: 972-420-8345 Fax: 972-420-7770 | |
Richard D Karem, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 777 Hospital Way, Pocatello, ID 83201 Phone: 208-239-2722 Fax: 208-239-3759 | |
Scott S Petty, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1777 E Clark St, Suite 330, Pocatello, ID 83201 Phone: 208-233-1033 |